Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Transdermal ALC919 Microporation Study in Healthy Volunteers
jRCT2011220042Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing ALC919 transdermal microporation with Placebo transdermal microporation (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2023; status: recruiting.
02
Drugs
ALC-919
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2011220042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220042.